OCIAD2

Across TCGA pan-cancer cohorts, OCIAD2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated OCIAD2 data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher OCIAD2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OCIAD2 expression acts as an unfavorable survival marker.

LUSC, COAD, and KIRC are the cancer types where OCIAD2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	III,IV	0.140	0.664	.016	12	view →
COAD	OS	Median	All	0.168	0.806	.002	12	view →
KIRC	OS	Median	All	0.249	0.810	.011	6	view →
LIHC	DFS	Median	All	0.100	0.543	.038	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

OCIAD2–LUSC (OS)

Open the LUSC breakdown →